WHAT DO “ULTRA-RAPID” ACTING INSULINS REALLY LOOK LIKE?:
A Deep Dive in the Latest and Most Effective
Insulin Strategies to Improve Time in Range
An Online CME Activity – 1.0 CEUs
JUNE 16, 2021 | 4:00PM PT
HELP YOUR PATIENTS IMPROVE THEIR TIME IN RANGE
We all know that ongoing adjustment of mealtime insulin has been a significant clinical challenge in people living with type 1 diabetes and those with type 2 diabetes requiring insulin—but ultra-rapid acting insulins can address this important unmet need in diabetes management. Join Drs. Edelman and Pettus as they discuss the real-world application of ultra-rapid acting insulins and ask them questions live to help your patients improve their time in range.
STATEMENT OF NEED
Proper initiation, titration and ongoing adjustment of mealtime insulin has always been a significant clinical challenge, not only in the majority of people living with type 1 diabetes but also in those with type 2 diabetes requiring prandial insulin. The pharmacokinetics of “rapid acting” insulins have a slow onset of action and delayed clearance that does not match nutrient absorption, commonly leading to post prandial glucose elevation, delayed hypoglycemia and reduced time in range.
The new “ultra-rapid” acting insulins address this important unmet need in diabetes management. The improved Pk/Pd profiles of these unique formulations allow for less “highs” and “lows”, improved glycemia variability and time in range.
This course is designed for endocrinologists, primary care physicians, nurse practitioners, physician assistants, certified diabetes care and education specialists, pharmacists, and other healthcare providers wanting to expand their knowledge and application of ultra-rapid acting insulins.
AFTER COMPLETING THIS ACTIVITY, THE PARTICIPANT SHOULD BE BETTER ABLE TO:
1. Review Pk/Pd characteristics of the modern, mealtime insulins including injectable and inhaled
2. Describe the important strategies for the timely initiation, appropriate titration and ongoing adjustments of these novel mealtime insulins using patient education/titration methods
3. Utilize continuous glucose monitoring to enable patients to initiate and titrate ultra-rapid acting insulins
4. Describe practical techniques for successful use of these ultra-rapid insulins
*Steven V. Edelman, MD
TCOYD Founder & Director
Dr. Edelman is the founder and director of Taking Control Of Your Diabetes (TCOYD), a professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California, San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego. He is also the director of the Diabetes Care Clinic at the VA Medical Center. Dr. Edelman, who has type 1 diabetes himself, has written more than 200 articles, five books, and has won numerous awards for teaching and humanitarianism. He has been chosen by the medical students at UCSD as the ‘teacher of the year’ numerous times. Among his many honors, Dr. Edelman has received the ‘Diabetes Educator Of The Year’ award by the American Diabetes Association, the ‘Distinction in Endocrinology’ award by the American Association of Clinical Endocrinologists, and named ‘Top 1% of U.S. Endocrinologists’ by US News and World Report.
*Jeremy Pettus, MD
Type 1 Track and Professional Education Director, Endocrinologist, Associate Professor of Medicine, UCSD School of Medicine
Dr. Jeremy Pettus was diagnosed with type 1 diabetes when he was 15 years old. Since that time he has dedicated his career to educating and treating others like himself. He is currently an Endocrinologist and Assistant Professor of Medicine at the University of California, San Diego. There, he focuses primarily on clinical trials to develop and test new and innovative therapies for people living with diabetes. These include studies ranging from medications to reverse or slow the disease once it occurs, to islet cell transplantation strategies, to device studies such as artificial pancreas technology. As somebody who has the disease himself, sees patients with type 1, and is actively working on curing/treating the disease, we are honored to have him as our Type 1 Track director. Dr. Pettus travels across the country and the world meeting other leading physicians and scientists and brings this information directly to TCOYD conference participants.
This activity is jointly provided by Global Education Group and Taking Control Of Your Diabetes.
This activity is supported by an educational grant from MannKind.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and TCOYD. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-21-001-L01-P) This is a knowledge based activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must pass the posttest with at least 70%. They must also complete the activity evaluation and submit it. Certificates will be emailed within 4-6 weeks of completion.
Fee Information & Refund/Cancellation Policy
This is a complimentary educational activity. You may cancel your registration at any time prior to the event. Contact Sarah Severance at email@example.com with any questions or concerns.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter:
Reported Financial Relationship:
Speaker’s Bureau: AstraZeneca, Lilly, MannKind, Merck, Sanofi-Aventis
Advisory Board: AstraZeneca, BrightSight, Companion Medical, Lilly, Merck, Sanofi-Aventis, Senseonics, TeamType1
Reported Financial Relationship:
Consultant/Independent Contractor: Dexcom, Eversense, Insulet, Lexicon Pharmaceuticals, Lilly, Mannkind, Novo Nordisk, Sanofi-Aventis
Grant/Research Support: Novo Nordisk
Speaker’s Bureau: MannKind
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager:
Lindsay Borvansky, Reported Financial Relationship: Nothing to disclose
Andrea Funk, Reported Financial Relationship: Nothing to disclose
Liddy Knight, Reported Financial Relationship: Nothing to disclose
Ashley Cann, Reported Financial Relationship: Nothing to disclose
Sarah Severance, Reported Financial Relationship: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and TCOYD do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.